Literature DB >> 8057398

Acute zolpidem poisoning--analysis of 344 cases.

R Garnier1, E Guerault, D Muzard, P Azoyan, A E Chaumet-Riffaud, M L Efthymiou.   

Abstract

Zolpidem is a new short acting hypnotic agent, first launched in France in 1988. Three hundred forty-four cases of intentional acute overdoses are reviewed retrospectively. Patients were predominantly female (70%) in their third or fourth decade. Ingested doses of zolpidem ranged between 10 and 1400 mg (one pack or less in 80%). Half of the patients ingested other substances (psychotropic drugs and alcohol) concomitantly. Signs of intoxication were observed in two thirds of the population but could be attributed to zolpidem in only 105 cases: drowsiness (N = 89) occurred at doses of 140 to 440 mg; coma (N = 4) or respiratory failure (N = 1). Other symptoms were rare (excepted vomiting, N = 7). Of the rare electrocardiographic or biological abnormalities, none appeared to be directly related to zolpidem. Therapy for intoxication was usually limited to supportive measures and/or gastric lavage. Symptoms of intoxication rapidly remitted in 91% of cases. Three percent of patients with multiple drug ingestion recovered despite severe complications during intensive care. Fatalities were reported for 6% but could not be directly linked to zolpidem. Previous published reports are confirmed: zolpidem acute overdose is generally benign and requires no specific therapeutic measures.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057398     DOI: 10.3109/15563659409011040

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  9 in total

1.  Hepatotoxicity associated with zolpidem treatment.

Authors:  D Karsenti; P Blanc; Y Bacq; E H Metman
Journal:  BMJ       Date:  1999-05-01

2.  Acute zolpidem overdose leading to coma and respiratory failure.

Authors:  A Hamad; N Sharma
Journal:  Intensive Care Med       Date:  2001-07       Impact factor: 17.440

Review 3.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Over-the-counter and prescription sleep medication and incident stroke: the REasons for Geographic and Racial Differences in Stroke study.

Authors:  Megan E Petrov; Virginia J Howard; Dawn Kleindorfer; Michael A Grandner; Jennifer R Molano; George Howard
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-08-10       Impact factor: 2.136

Review 5.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 6.  The clinical and forensic toxicology of Z-drugs.

Authors:  Naren Gunja
Journal:  J Med Toxicol       Date:  2013-06

7.  Zolpidem : Forensic aspects for the toxicologist and pathologist.

Authors:  Timothy P Rohrig; Christine M Moore
Journal:  Forensic Sci Med Pathol       Date:  2005-06       Impact factor: 2.456

8.  An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Int J Neuropsychopharmacol       Date:  2019-04-01       Impact factor: 5.176

9.  A case of suicide attempt with Zolpidem - will Zolpidem show up on standard urine toxicology screening?

Authors:  Nadav Willner; Elad Schiff
Journal:  EXCLI J       Date:  2014-05-06       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.